Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ENZY

(ENZY) (ENZY) Stock Price, News & Analysis

(ENZY) logo

About (ENZY) Stock (NASDAQ:ENZY)

Advanced Chart

Key Stats

Today's Range
$11.85
$11.85
50-Day Range
N/A
52-Week Range
$6.30
$12.35
Volume
N/A
Average Volume
120,557 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive ENZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ENZY) and its competitors with MarketBeat's FREE daily newsletter.

ENZY Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ENZY Stock Analysis - Frequently Asked Questions

(ENZY) (NASDAQ:ENZY) announced its quarterly earnings data on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. The firm's quarterly revenue was down 14.3% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ENZY) investors own include Caesarstone (CSTE), Laredo Petroleum (LPI), Allena Pharmaceuticals (ALNA), Camtek (CAMT), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB) and Aquinox Pharmaceuticals (AQXP).

Company Calendar

Last Earnings
5/17/2017
Today
6/20/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ENZY
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ENZY) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners